Angelo Nocivelli Institute of Molecular Medicine, Division of Gynecologic Oncology, University of Brescia, Viale Europa 11, 25123 Brescia, Italy.
J Transl Med. 2013 Jul 2;11:162. doi: 10.1186/1479-5876-11-162.
The aim of the present study was to investigate within ovarian carcinoma and normal ovarian biopsies the gene expression of multiple secretoglobin family members relative to mammaglobin B, which we previously reported as a promising novel ovarian carcinoma prognostic marker.
Using quantitative real-time Reverse Transcription PCR we tested 53 ovarian carcinoma and 30 normal ovaries for the expression of 8 genes belonging to the secretoglobin family: mammaglobin A, lipophilin A, lipophilin B, uteroglobin, HIN-1, UGRP-1, RYD5 and IIS. Next, we decided to expand the LipB gene expression analysis to a further 48 ovarian carcinoma samples, for a total of 101 tumor tissues of various histologies and to study its protein expression by immunohistochemistry in formalin-fixed paraffin-embedded tumors and normal ovaries. Finally, we correlated lipophilin B gene and protein expression to conventional patient clinico-pathological features and outcome.
We found significant mammaglobin A, lipophilin A, lipophilin B and RYD5 gene overexpression in ovarian carcinomas compared to normal ovaries. Lipophilin B mRNA showed a higher presence in tumors (75.4%) compared to normal ovaries (16.6%) and the most significant correlation with mammaglobin B mRNA (rs =0.77, p < 0.001). By immunohistochemical analysis, we showed higher lipophilin B expression in the cytoplasm of tumor cells compared to normal ovaries (p < 0.001). Moreover, lipophilin B gene overexpression was significantly associated with serous histology (serous vs clear cell p = 0.027; serous vs undifferentiated p = 0.007) and lower tumor grade (p = 0.02). Lower LipB mRNA levels (low versus high tertiles) were associated to a shorter progression-free (p = 0.03, HR = 2.2) and disease-free survival (p = 0.02, HR = 2.5) by univariate survival analysis and, importantly, they remain an independent prognostic marker for decreased disease-free (p = 0.001, HR = 3.9) and progression-free survival (p = 0.004, HR = 2.8) in multivariate Cox regression analysis.
The present study represents the first quantitative evaluation of secretoglobin gene expression in normal and neoplastic ovarian tissues. Our results demonstrate lipophilin B gene and protein upregulation in ovarian carcinoma compared to normal ovary. Moreover, lipophilin B gene overexpression correlates with a less aggressive tumor phenotype and represents a novel ovarian carcinoma prognostic factor.
本研究旨在研究多个分泌球蛋白家族成员在卵巢癌和正常卵巢活检中的基因表达情况,这些成员的基因表达相对于我们之前报道的作为有前途的新型卵巢癌预后标志物的乳腺球蛋白 B。
使用定量实时逆转录 PCR,我们测试了 53 例卵巢癌和 30 例正常卵巢的 8 种基因的表达:乳腺球蛋白 A、脂磷蛋白 A、脂磷蛋白 B、子宫球蛋白、HIN-1、UGRP-1、RYD5 和 IIS。接下来,我们决定将 LipB 基因表达分析扩展到另外 48 例卵巢癌样本,总共对各种组织学类型的 101 个肿瘤组织进行研究,并通过免疫组织化学法在福尔马林固定石蜡包埋的肿瘤和正常卵巢中研究其蛋白表达。最后,我们将脂磷蛋白 B 基因和蛋白表达与常规患者临床病理特征和结果相关联。
与正常卵巢相比,我们发现卵巢癌中明显存在乳腺球蛋白 A、脂磷蛋白 A、脂磷蛋白 B 和 RYD5 基因的过度表达。与正常卵巢(16.6%)相比,脂磷蛋白 B mRNA 在肿瘤中(75.4%)的存在更高,并且与乳腺球蛋白 B mRNA 具有最显著的相关性(rs=0.77,p<0.001)。通过免疫组织化学分析,我们显示肿瘤细胞胞质中的脂磷蛋白 B 表达高于正常卵巢(p<0.001)。此外,脂磷蛋白 B 基因的过度表达与浆液性组织学(浆液性与透明细胞性比较,p=0.027;浆液性与未分化性比较,p=0.007)和较低的肿瘤分级(p=0.02)显著相关。较低的 LipB mRNA 水平(低与高三分位)与较短的无进展生存期(p=0.03,HR=2.2)和无病生存期(p=0.02,HR=2.5)相关通过单变量生存分析,重要的是,它们仍然是降低无病生存期(p=0.001,HR=3.9)和无进展生存期(p=0.004,HR=2.8)的独立预后标志物在多变量 Cox 回归分析中。
本研究代表了对正常和肿瘤卵巢组织中分泌球蛋白基因表达的首次定量评估。我们的结果表明,与正常卵巢相比,脂磷蛋白 B 基因和蛋白在卵巢癌中上调。此外,脂磷蛋白 B 基因的过度表达与侵袭性较低的肿瘤表型相关,是一种新型的卵巢癌预后标志物。